SciSparc granted patent from Australia for reduction of opioids use

SciSparc announced its had been received notice of acceptance for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment. The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents. “The fact that SciSparc’s number of granted patents continues to grow is proof recognizing the innovation that characterizes the technologies in the Company’s pipeline. In this case, our unique technology allows us to harness the ability to treat pain through opioids while using significantly lower concentrations than those used on the market today and allows us to continue to fulfill our promise to offer both effective and safe treatments,” said SciSparc’s Chief Executive Officer, Oz Adler.